Fucoidan Alleviates Renal Fibrosis in Diabetic Kidney Disease via Inhibition of NLRP3 Inflammasome-Mediated Podocyte Pyroptosis

Fucoidan Alleviates Renal Fibrosis in Diabetic Kidney Disease via Inhibition of NLRP3 Inflammasome-Mediated Podocyte Pyroptosis

Background: Fucoidan (FPS) has been widely used to treat renal fibrosis (RF) in patients with diabetic kidney disease (DKD); however, the precise therapeutic mechanisms remain unclear. Recently, research focusing on inflammation-derived podocyte pyroptosis in DKD has attracted increasing attention....

Full description

Bibliographic Details
Main Authors: Mei-Zi Wang, Jie Wang, Dong-Wei Cao, Yue Tu, Bu-Hui Liu, Can-Can Yuan, Huan Li, Qi-Jun Fang, Jia-Xin Chen, Yan Fu, Bing-Ying Wan, Zi-Yue Wan, Yi-Gang Wan, Guo-Wen Wu
Format: Article
Language:English
Published: Frontiers Media S.A. 2022-03-01
Series:Frontiers in Pharmacology
Subjects:
fucoidan
diabetic kidney disease
renal fibrosis
podocyte pyroptosis
NLRP3 inflammasome
Online Access:https://www.frontiersin.org/articles/10.3389/fphar.2022.790937/full

Internet

https://www.frontiersin.org/articles/10.3389/fphar.2022.790937/full

Similar Items